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ABSTRACT
Factors that determine the biological and clinical behavior of prostate
cancer are largely unknown. Prostate tumor progression is characterized by
changes in cellular architecture, glandular organization, and genomic com-
position. These features are reflected in the Gleason grade of the tumor and
in the development of aneuploidy. Cellular architecture and genomic stability
are controlled in part by centrosomes, organelles that organize microtubule
arrays including mitotic spindles. Here we demonstrate that centrosomes are
structurally and numerically abnormal in the majority of prostate carcino-
mas. Centrosome abnormalities increase with increasing Gleason grade and
with increasing levels of genomic instability. Selective induction of centro-
some abnormalities by elevating levels of the centrosome protein pericentrin
in prostate epithelial cell lines reproduces many of the phenotypic character-
istics of high-grade prostate carcinoma. Cells that transiently or permanently
express pericentrin exhibit severe centrosome and spindle defects, cellular
disorganization, genomic instability, and enhanced growth in soft agar. On
the basis of these observations, we propose a model in which centrosome
dysfunction contributes to the progressive loss of cellular and glandular
architecture and increasing genomic instability that accompany prostate
cancer progression, dissemination, and lethality.
INTRODUCTION
Prostate carcinoma is the most common gender-specific cancer in the
United States, accounting for nearly one-third of all cancers affecting men
(1). The lifetime risk of developing invasive prostate carcinoma in the
United States is ;20% (2–5), whereas that of octogenarians based on
histopathological examination of the prostate at autopsy approaches 80%
(6). Despite the high incidence of prostate carcinoma, the lifetime risk of
dying from the disease is much lower, currently estimated to be ;3.6%
(1 of 28; Surveillance Epidemiology & End Results, NCI, 2000, personal
communication). These epidemiological trends, which may intensify in
the coming decades because of the aging of the Baby Boom generation
and our increasing ability to recognize tumors at earlier stages, mean that
180,000 new cases of prostate cancer will be diagnosed in the coming
year in the United States.
Radical prostatectomy is the most common therapy for the small group
of patients with high-grade tumors. However, there currently are no
sound medical facts to direct treatment of the majority of patients that
present with lower grade tumors (7, 8). Because a subgroup of patients
with low-grade carcinoma ultimately develop aggressive, often lethal
cancers, current therapeutic recommendations are to treat all patients with
an intent to cure (7, 8). Thus, the most pressing need in the management
of prostate carcinoma is to develop a noninvasive test to distinguish
clinically indolent (low-grade) carcinoma from potentially fatal disease
(see “Discussion”; Ref. 9). This test would spare the majority of patients
with indolent prostate cancer from unnecessary prostatectomy. Reducing
such surgeries would result in significant cost savings in health care,
decreased therapy-related morbidity, and more focused therapy on the
more homogeneous group of patients with aggressive disease, where the
efficacy of newer therapies could be assessed more quickly (9).
One of the best predictors of prostate cancer progression is the
Gleason score, a numerical measure compiled from the two most
prevalent histological Gleason grades. The Gleason grade reflects
cytoarchitectural features that become increasingly aberrant with tu-
mor progression (10, 11). Recent results indicate that the parameter
with the greatest predictive power is the proportion of tumor with the
highest Gleason grades (4 and 5; Ref. 12). An intimate relationship
between Gleason grade, aneuploidy, and unfavorable clinical outcome
has long been known (13–17). This suggests that the molecular
components and subcellular structures that control cell and tissue
architecture and genetic fidelity are likely to contribute to tumor
progression. These parameters have the potential to dictate the clinical
behavior of tumors and thus serve as predictors of aggressive cancer.
In a search for cellular elements that contribute to the constellation
of cellular and genetic features found in high Gleason grade prostate
carcinoma, we focused on centrosomes (18). Centrosomes are tiny
cellular organelles that nucleate microtubule growth and organize the
mitotic spindle for segregating chromosomes into daughter cells (re-
viewed in Refs. 19 and 20). As organizers of microtubules, centro-
somes also play an important role in many microtubule-mediated
processes, such as establishing cell shape and cell polarity, processes
essential for epithelial gland organization (21–24). Centrosomes also
coordinate numerous intracellular activities in part by providing dock-
ing sites for regulatory molecules, including those that control cell
cycle progression, centrosome and spindle function, and cell cycle
checkpoints (20, 24–29). Because high Gleason grade prostate cancer
is characterized by defects in the same set of cellular processes
controlled by centrosomes, we hypothesized that centrosome dysfunc-
tion may be the biological basis for these phenotypic abnormalities.
In this report, we show that centrosome defects are found in essentially
all high-grade prostate cancers. Moreover, centrosome defects are present
in low-grade tumors, and they increase with increasing Gleason grade and
with increasing genomic instability. Artificial induction of centrosome
abnormalities in cultured prostate cells by overexpression of the centro-
some protein pericentrin reproduces many features of aggressive prostate
cancer. We discuss our results in terms of a centrosome-mediated mech-
anism for tumor progression. Centrosome abnormalities in prostate can-
cer could be exploited to develop markers for tumor virulence and
selective therapies that target tumor-specific centrosome abnormalities,
thus circumventing the greatest limitation of current chemotherapy–its
lack of tumor selectivity.
MATERIALS AND METHODS
Immunohistochemical Detection of Centrosomes in Archival Tissue
Sections of Prostate Carcinoma. Archived cases of invasive prostate carci-
noma treated by radical prostatectomy were selected from the files of the
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Department of Pathology of the University of Massachusetts Medical
Center accrued between the months of July 1995 and June of 1997. Criteria
for inclusion were availability of archival tissue blocks from which good
quality histology sections could be prepared. Sections with the highest
Gleason grade from each radical prostatectomy were selected because there
is good indication that the highest Gleason grade is the best indicator of
clinical outcome (12). We analyzed only high quality tissue sections (109
total) from radical prostatectomies with invasive carcinoma representing
Gleason grades 2–5 and from metastatic prostate carcinoma (31 cases).
Immunostaining for pericentrin was judged satisfactory when the charac-
teristic single or paired centrosome pattern (30) was detected in nonneo-
plastic cells adjacent to the tumor (Table 1).
Immunohistochemistry for pericentrin (18) was performed on serial paraffin
sections (5 mm thick) attached to positively charged glass slides (Ventana
Medical Systems). The first section of each series was stained with H&E to
confirm the presence and grade of the carcinoma and to map the tumor within
the section. Parallel sections were processed for centrosome staining by im-
munohistochemistry. Sections were first heated in a microwave pressure
cooker for 30 min in a solution containing 0.2 mM EDTA (18) to render
Fig. 1. Centrosome abnormalities in invasive
prostate carcinoma compared with adjacent normal
tissue. Sections from radical prostatectomies were
stained for pericentrin (brown) as described in
“Materials and Methods.” A, prominent centrosome
abnormalities are seen in small tumor glands (be-
tween arrowheads) compared with centrosomes in
three large normal glands (top left, top, and bottom
right). 3100. B–G: higher magnification (31000)
of centrosomes in tumor cells (C–G) and nontumor
cells (B). Centrosomes in tumor cells (arrowheads)
are larger in diameter (C, G, arrowheads), elon-
gated (E, arrowheads), multiple and apparently
fragmented (D and F), and contain more pericentrin
(C–G) than control centrosomes (arrowheads in B).
Most tumors had combinations of centrosome
defects.
Table 1 Centrosome abnormalities in prostate carcinoma
Tumor typea
Abnormal centrosomesb
Non-tumor epitheliumc Tumor epithelium
Metastatic prostate carcinoma 0/31d 31/31
Prostate carcinoma confined to the prostate 0/97 101/109
a Tumors were identified by cellular, glandular, and nuclear features in H&E-stained
sections. Parallel sections were stained for pericentrin by the immunoperoxidase technique
to detect centrosomes and counterstained with hematoxylin only.
b For all samples in this analysis, paraffin-embedded tissues were sectioned,
reacted with pericentrin antibodies and immunoperoxidase methods, and examined by
light microscopy. The centrosome defects in tumor tissue were statistically higher
than control non-tumor glands (P , 0.0001, Fisher’s exact test). Centrosomes were
considered abnormal if they had a diameter at least twice that of centrosomes in
normal prostate gland epithelium, if they were structurally abnormal (elongated), if
they were present in more than two copies/cell, and if they had increased cytoplasmic
and or centrosomal staining levels of the centrosome protein pericentrin (18).
c Non-tumor epithelium was present within the same section that contained the tumor
in the majority of the cases (97 of 109).
d Control cells in metastatic organs included cells of that organ (lymphocytes and
hematopoietic cells in lymph nodes and bone marrow) as described previously (18).
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centrosome antigens immunoreactive to pericentrin antibodies (30–32). Anti-
body was diluted 1:1000 in TBST [50 mM Tris (pH 6.5), 150 mM NaCl, and
0.5% Tween 20], added to sections at room temperature, and incubated for 1 h.
Biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) was
applied in TBST for 1 h and amplified by the avidin-biotin-complex method as
described (ABC; Vector Laboratories, Burlingame, CA). To block endogenous
biotin- and avidin-binding sites, sections were treated with a solution of biotin,
followed by a solution of avidin before application of the primary antibody. To
avoid nonspecific binding by primary and secondary antibodies, washing
solutions contained 5% w/v BSA and 5% v/v goat serum. Endogenous perox-
idase was blocked by preincubation in a solution of 3% H2O2. After immu-
nostaining, sections were lightly counterstained in hematoxylin.
Criteria for Centrosome Defects. We considered centrosomes abnormal
if they had a diameter at least twice that of centrosomes in normal prostate
gland epithelium, if they were present in numbers .2, and if they were
structurally abnormal, as described previously (18). In some cases, we ana-
lyzed levels of the centrosome protein pericentrin at centrosomes and in the
cytoplasm by quantifying the opacity/translucence of immunoperoxidase stain-
ing. Briefly, bright-field immunoperoxidase images of tumor and normal
prostate glands taken at 31000 were digitally color-inverted so the immu-
noperoxidase product was a bright signal whose luminosity was proportional to
the intensity of the original brown signal. Signals were measured as the integral
of a 5-mm area about five times the size of a centrosome, as delineated with the
marquee function of Photoshop. Signal emanating from the neighboring cyto-
plasm was subtracted from the respective centrosome measurement. For cy-
toplasmic pericentrin measurements, background signals emanating from non-
tissue sources were subtracted. Inclusion of internal controls (normal glands
present within the same section) allowed us to obtain semiquantitatively
measurements of pericentrin levels within and between tumors. This approach
has been used to establish differences in protein levels of other proteins (33).
Members of our Biostatistics core (Dr. Chung Cheng, University of Massa-
chusetts Medical School) performed statistical analysis.
In Situ Hybridization with Chromosome-specific Centromere Probes.
For in situ hybridization studies, tissue sections parallel to those stained for
centrosomes were deparaffinized and heated in a microwave pressure cooker
for 20 min in a solution containing 0.01 M sodium citrate (pH 6.0). After
cooling to room temperature, sections were treated with a solution of pepsin
(40 mg/ml) in 0.1 N HCl for 10 min. Pepsin digestion was stopped by washing
the sections several times in 23 SSC at room temperature, and slides were
dehydrated in a series of alcohols and air-dried. Biotinylated probes to the
centromeric regions of chromosomes 1 or 8 were added in hybridization buffer,
and slides were mounted, sealing coverslips with rubber cement. Target DNA
and probes were codenatured in a Hybrite oven (Vysis, Downers Grove, IL;
Ref. 18), and slides were washed several times in SSC buffers for maximum
stringency (Vysis), processed to detect signals (NEN Life Science Products,
Boston, MA), and lightly counterstained with hematoxylin to reveal nuclei.
Data are shown for chromosome 8 (Figs. 5 and 7) and is similar to that
observed with probes to chromosome 1 (not shown).
A total of 100–120 nuclei in tumor and nontumor areas of the section
(identified by hematoxylin counterstain) were scored for centromere signals.
CIN3 was determined by computing the fraction of cells with signals greater
than the mode (34), a parameter known to underestimate the true CIN level
(18, 34). To avoid the compounding effect of nuclear truncation artifact in
tissue sections, we computed only chromosome gains. Cells in the G2 phase of
the cell cycle, which normally have four copies of each chromosome, were
distinguishable from cells with supernumerary chromosomes because sister
chromosomes (and centromere signals) in these cells occur in pairs.
Pericentrin Transfections into Normal or Tumor-derived Prostate Cell
Lines. Full length HA-tagged pericentrin in pcDNA I (2 mg; Ref. 32; Invitro-
gen) was used for transient transfection (Lipofectamine; Life Technologies,
Inc., Gaithersburg, MD) of the 1542-NPTX cell line derived from normal
prostate epithelium by transformation with E6 and E7 from human papillo-
mavirus type 16 (35). Cells transfected with vector alone served as controls.
Permanent pericentrin-expressing PC-3 cells were constructed by cloning
full-length HA-pericentrin into the pRetroON vector (Clontech), which codes
for a reverse tetracycline transactivator protein and contains tetracycline trans-
activator responsive elements that drive transcription of the gene of interest.
The transactivator is reported to bind and activate the promoter in the presence
of tetracycline/doxycycline. After sequence confirmation, the cDNA was in-
troduced into PC-3 cells (American Type Culture Collection) by transient
transfection (as above), and 24 permanent lines were obtained after antibiotic
selection (Clontech); cell lines expressing vector alone served as controls. We
found that HA-pericentrin in these lines was expressed in the absence of
doxycycline and did not significantly increase in the presence of doxycycline.
The pericentrin-expressing cells exhibited dramatically different features than
control cells in the absence of the drug; these features did not noticeably
increase in the presence of drug, and they were indistinguishable from features
observed in transiently transfected 1542 NPTX cells (Fig. 6) and COS cells
(32). Protein expression in the absence of induction from the pRetroON vector
and the lack of inducibility of the vector has been noted by Clontech,4 and they
have discontinued its sale. Imperfections in the inducibility of the vector did
not impact on our study because we obtained several permanent pericentrin-
expressing cell lines. In this study, we present data from cells treated with
doxycycline for 48 h.
Immunofluorescence Analysis of Cell Lines. Pericentrin-expressing 1542
NPTX cells (48 h after transfection) and PC-3 cells were fixed in cold
3 The abbreviations used are: CIN, chromosomal numerical instability; HA, hemag-
glutinin antigen.
4 Personal communication.
Fig. 2. Centrosome diameter and number are in-
creased, and pericentrin levels are elevated in prostate
carcinoma. Measurements from a single grade 3 pros-
tate carcinoma are shown. A–D, densitometric meas-
urements of centrosomes and cytoplasm were per-
formed on tumor tissues and nontumor tissues as
described in “Materials and Methods” (33). Immu-
noperoxidase reaction product was quantified by
measuring translucence in boxes shown in A and B.
Insets in A and B, higher magnification of centro-
somes in measuring boxes to show dramatic differ-
ences in centrosome size. A: left box, cytoplasmic
pericentrin; right box, centrosomal pericentrin. B: left
box, centrosomal pericentrin; right box, cytoplasmic
pericentrin. C and D, an average of eight measure-
ments of centrosomal and cytoplasmic pericentrin in
nontumor (Normal) and tumor tissues, respectively.
Centrosome size (E) and number (F, normalized to
nuclei) were determined as described in “Materials
and Methods.” Each column in E and F represents the
average of .100 measurements taken from one tu-
mor. Ps in C–F were obtained by paired Student’s t
test. Bars, SE.
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methanol and costained for g-tubulin to label centrosomes and HA to locate
transfected cells (1542 NPTX) as described (32). DNA was stained with
49,6-diamidino-2-phenylindole, and levels were quantified as described (32).
Growth in Agarose of Prostate Cell Lines Permanently Expressing
Pericentrin. To study the in vitro behavior of cells with deregulated expres-
sion of pericentrin, we used the agarose colony assay of Bishop with minor
modifications (36). One hundred thousand HA-pericentrin-expressing cells or
empty vector cells were plated in duplicate in six-well plates in 0.35%
low-melting point agarose over a cushion of 0.7% agarose. Cells were fed full
growth medium (10% FCS, 90% RPMI, plus antibiotics and glutamine) and
assessed for growth at 3 and 7 days using an inverted microscope equipped
with a film camera. Images were then taken at 340, and colonies were counted
and sized after an additional 310 projection onto a screen. A total of 10
images/cell line were analyzed (between 500 and 1000 colonies).
RESULTS
Centrosome Abnormalities in Prostate Carcinoma. In this
study, we analyzed prostate tumors of different cytological grades for
the presence of centrosome defects. We selected the area with the
highest Gleason grade within each radical prostatectomy, because this
parameter appears to be the single most important determinant of
clinical outcome (12). We avoided the breakdown of data by Gleason
score, as customarily done in clinical data representations, because it
represents a compound measure of multiple Gleason grades and may
thus obscure the significance of our observations. We examined
paraffin sections from radical prostatectomies containing tumors rang-
ing from Gleason grades 2 to 5 (n 5 103). Gleason grade 1 tumors
were not included, because they are rare and relatively difficult to
recognize, and because they may have a different ontogenic derivation
than more common carcinomas (37). We also analyzed a group of
metastatic prostate carcinomas comprised primarily of lymph node
and bone marrow metastases (n 5 31).
Three parameters were initially used to monitor centrosome abnor-
malities: larger diameter, elevated number, and abnormal structure
(Figs. 1 and 2). These parameters were used previously by our group
to provide the first evidence for centrosome abnormalities in malig-
nant tumors of multiple tissue origin (18). Analysis of metastatic
carcinomas using these criteria demonstrated that all had abnormal
centrosomes (31 of 31; Table 1). The proportion of tumor with
centrosome defects varied from 15% to virtually 100% of tumor cells.
These results confirm our previous results showing that centrosomes
are abnormal in prostate tumors (18) and extend these observations to
demonstrate that centrosome abnormalities in metastatic tumors ap-
pear to be universally present and severe. The majority of carcinomas
confined to the prostate (Gleason grades 2–5) also had abnormal
centrosomes (101 of 109, Table 1; Fig. 1). However, abnormalities in
this heterogeneous group of tumors were more variable than those
observed in metastatic carcinomas. Some exhibited defects in only
one or two of the three parameters, and the proportions of tumor tissue
with centrosome abnormalities were generally lower than in meta-
static tumors. In no instance did we observe centrosome abnormalities
in nontumor tissues adjacent to tumors (Table 1; Fig. 1).
We reasoned that variability in centrosome defects in this hetero-
geneous mix of tumors might reflect differences in biological behav-
ior and Gleason grade. To test this, we analyzed six cases each of
Fig. 3. Centrosome abnormalities increase with increasing Gleason grade: pictorial view. Histological features of a normal prostate gland (A) and prostate carcinoma of Gleason
grades 3 (D) and 5 (G) on H&E-stained sections are shown. Areas similar to those imaged in the left column were stained for pericentrin at 3400 (B, E, and H) and 31000 (C, F,
and I). With advancing Gleason grade, centrosomes become progressively larger, structurally more abnormal, and greater in number.
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tumors with Gleason grades 2 through 5 for the three parameters of
centrosome defects. In addition, we examined in detail the distribution
and levels of pericentrin, a highly conserved integral centrosome
protein involved in centrosome and spindle organization and chromo-
some segregation (30–32). Because our previous work had strongly
suggested that levels of the centrosome protein pericentrin were
higher in tumor versus nontumor tissues (18), we analyzed pericentrin
levels using a quantitative method established for tissues processed
for immunohistochemistry (Ref. 33; Fig. 2, C and D). Of the five
parameters measured, four were significantly higher in tumors of high
Gleason grades (combined 4 and 5) compared with those of low
Gleason grades (combined 2 and 3; Figs. 3 and 4). Centrosome size
and number were 2-fold higher in tumors of high Gleason grade (Fig.
4, A and B), and pericentrin levels at the centrosome and in the
cytoplasm were significantly higher in high-grade tumors (Fig. 4, C
and D). In contrast, neither the severity nor prevalence of structural
abnormalities in centrosomes increased with higher Gleason grade
(data not shown). Among the structural defects were elongated cen-
trosomes (length:width ratio .5; Figs. 1E and 3I) that were never
observed in normal human prostate cells. This suggested that elon-
gated centrosomes were tumor specific and had potential to serve as
a diagnostic marker (see “Discussion”). For all five categories of
centrosome defects, the distribution within tumors was somewhat
heterogeneous, a pattern reminiscent of that reported for tumor DNA
content (38–41).
Relationship between Centrosome Abnormalities and Chromo-
somal Instability. Because centrosomes play a role in the mainte-
nance of genomic stability through control of mitotic chromosome
segregation, we asked if there was a correlation between abnormal
centrosomes and genomic instability, specifically CIN. CIN, as first
described by Lengauer et al. (34), is a measure of the nonmodal
distribution of chromosomes that is thought to result from persistent
missegregation of chromosomes during mitosis. In this study, we
examined the nonmodal distribution of chromosome 8 in prostate
tumors of different Gleason grades using centromere-specific nucle-
otide probes and in situ hybridization (see “Materials and Methods”
and Fig. 5). As expected, the extent of CIN in tumor tissues was
significantly greater than in nontumor tissues (Fig. 5). Interestingly,
the extent of CIN was significantly greater in Gleason grade 4/5 than
in Gleason grade 2/3 (Fig. 5C). Finally, the extent of CIN correlated
with the extent of centrosome abnormalities in parallel sections from
the same set of tumors (Fig. 5D), suggesting a relationship between
centrosome defects and genomic instability in prostate tumor progres-
sion.
Induction of Centrosome Defects in Prostate Cells by Ectopic
Expression of the Centrosome Protein Pericentrin Induces a Pros-
tate Tumor-like Phenotype. If elevated pericentrin levels and cen-
trosome defects observed in prostate tumor tissues contribute to
cellular and genetic changes that occur during tumor progression, they
may have the potential to induce similar changes when experimentally
induced in cultured cells. To directly test this idea, we induced
centrosome defects in prostate cells in vitro. We expressed a HA-
tagged pericentrin protein in cell lines derived from normal prostate
epithelium (1542-NPTX; Ref. 35) and from metastatic prostate cancer
(PC-3) both by transient transfection and by construction of perma-
nent cell lines (Figs. 6 and 7).
Elevation of pericentrin levels induced or exacerbated genetic in-
stability and cellular changes in 1542-NPTX and PC-3 cells, respec-
tively. 1542-NPTX cells transiently transfected with the HA-pericen-
trin construct exhibited numerous defects in centrosome size, shape,
and number (Fig. 6E) as revealed by immunofluorescence staining for
the centrosome protein g-tubulin (42). Defective centrosomes were
usually associated with structurally disorganized mitotic spindles, and
chromosomes associated with these abnormal spindles were often
misaligned and missegregated, indicating that the cells were under-
going aberrant mitoses (data not shown). Consistent with this idea
were dramatic changes in nuclear morphology observed in interphase
cells (lobate and misshapen nuclei, micronuclei, and multiple nuclei).
Moreover, DNA levels were elevated in a large proportion of HA-
pericentrin cells but not in control cells, demonstrating that pericentrin
expression induced aneuploidy/polyploidy (Fig. 6, B–D). Control
cells included cells transfected with vector alone (Fig. 6), a truncated
pericentrin construct (43) and b-galactosidase (data not shown). Sim-
ilar results were observed in green fluorescent protein-pericentrin
transfected cells (data not shown), indicating that this phenotype was
attributable to pericentrin overexpression and unrelated to the expres-
sion tag. These studies demonstrate that tumor-like changes in cellular
architecture and genetic composition can take place within one to
three cell cycles after HA-pericentrin expression.
To examine the long-term effects of HA-pericentrin expression, we
constructed permanent prostate tumor-derived cell lines (PC-3; see
“Materials and Methods”). The pericentrin-expressing PC-3 cell lines
(total, 24) exhibited several abnormal features compared with control
PC-3 cells containing empty vector (Fig. 7). Six cell lines were
examined in detail, and all gave a similar phenotype; below we
present data from one line (PeriPC-3–4.1). The presence of the
HA-pericentrin construct was confirmed by PCR analysis (data not
shown), and the HA-tagged pericentrin protein was detected by West-
ern blot (Fig. 7A). Defects in centrosomes, spindles, and nuclei were
significantly higher than in control cells and were strikingly similar to
defects observed in transiently transfected 1542-NPTX cells (Fig. 6)
Fig. 4. Centrosome abnormalities and pericentrin levels increase with increasing
Gleason grade: quantitative analysis. Centrosome diameter (A), centrosome number
(centrosome:nuclei ratio, B), centrosomal pericentrin (C), and cytoplasmic pericentrin (D)
were determined as described in “Materials and Methods.” The first column in A–D
represents the mean of measurements made on six tumors of grade 2 and six of grade 3
combined; the second column, similar numbers of grades 4 and 5. All values, a percentage
increase above nontumor cells present within the tissue sections (Y axis). The data
demonstrate that abnormal centrosome features are statistically greater in tumors of higher
Gleason grade. Ps obtained by paired Student’s t test. Bars, SE.
2216
CENTROSOME DEFECTS IN PROSTATE CANCER
and in prostate tumors (Figs. 1 and 2). DNA content analyzed by flow
cytometry (Fig. 7, E and F) and chromosomal instability assayed by
in situ hybridization with centromere probes for chromosome 8 (Fig.
7, C and D) were significantly higher in pericentrin-expressing PC-3
cells. Moreover, the cellular architecture of pericentrin-PC-3 cells was
dramatically altered (Fig. 7, G and H), and the cells grew more rapidly
in soft agar compared with controls (Fig. 7, I–K). Taken together,
these data demonstrate that expression of a single centrosome protein
in normal and prostate tumor cells can induce or exacerbate abnor-
malities in centrosome number and structure, cellular architecture,
nuclear morphology, cell growth, and genomic stability, features that
are characteristically altered in aggressive prostate tumors.
Fig. 5. Chromosome instability increases with increasing Gleason grade in invasive prostate carcinoma. In situ hybridization with a chromosome 8-specific centromeric probe in
a normal gland (A) and Gleason grade 4 prostate carcinoma (B). Inset in A, a low-power (340) view of an H&E-stained parallel section showing a normal gland (A) and high-grade
prostate carcinoma (B). The figure shows that significant numbers of tumor cells have greater than three signals/nuclei (B, arrowheads), whereas no cell shows more than two signals
in the normal epithelium (A). The extent of CIN (as the fraction of cells with chromosome 8 copy number .2) is greater in tumors of combined Gleason grades 4 and 5 than those
of Gleason grades 2 and 3 (C) and correlates with the cumulative extent of centrosome abnormalities (D, correlation coefficient, r 5 0.445). Bars, SE.
Fig. 6. Transient expression of pericentrin in
“normal” near-diploid prostate cells induces cen-
trosome defects, nuclear abnormalities, and aneu-
ploidy. 1542-NPTX cells were transfected with the
HA-pericentrin construct or vector alone and
grown for an additional 40 hours. A, Western blot
after immunoprecipitation of HA-pericentrin from
cell lysates. Microspectrofluorometric quantifica-
tion of DNA stained with 49,6-diamidino-2-
phenylindole shows that most HA-pericentrin-ex-
pressing cells (C) had higher or lower nuclear DNA
content than control cells (B). The average nuclear
DNA content of individual cells (D) was three
times greater than that of control cells (D, .100
cells/column). Bars, SE. Centrosome defects de-
tected in cells stained for g-tubulin were .20-fold
higher in HA-pericentrin-expressing cells (E).
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DISCUSSION
The results presented here demonstrate that centrosomes are
structurally and numerically abnormal in the vast majority of
metastatic and invasive prostate carcinomas. These abnormalities
are frequent and usually occur together in the same tumor. The
extent of centrosome abnormalities in invasive prostate carcinoma
correlates with the Gleason grade in that tumors with the highest
Gleason grade have more extensive centrosome abnormalities. The
extent of chromosome instability correlates with the extent of
centrosome abnormalities, both increasing with increasing Gleason
grade. These observations are consistent with the idea that centro-
some defects contribute to genomic instability during prostate
cancer progression. Support for this idea comes from data showing
that artificial induction of centrosome defects by pericentrin over-
expression can induce genetic instability, loss of cellular architec-
ture, and rapid cell growth in prostate cells.
The in vivo and in vitro data presented in this report implicate
centrosomes in the progression of prostate cancer. In our current
model (Fig. 8), centrosome dysfunction causes modification of the
microtubule cytoskeleton and contributes directly to cellular and
glandular disorganization and genomic instability, creating cells
that are predisposed to additional changes that lead to aggressive
tumor development. We do not know whether centrosome abnor-
malities develop in a progressive manner (Fig. 8, solid arrow) or in
a discontinuous fashion (Fig. 8, segmented arrows). Elucidation of
the mechanisms by which centrosome changes occur may provide
insights into the evolutionary pathway of the cytoarchitectural
features that occur during prostate cancer progression (44, 45).
Our observations of CIN in prostate carcinoma are consistent with
those made previously by Lengauer et al. (34) in colon carcinoma
cells, and they suggest that CIN may be the most important cause of
aneuploidy in colon and prostate tumors. Because centrosome abnor-
malities are found in essentially all carcinomas examined to date (18),
they may be a major cause of aneuploidy/CIN in solid tumors (18, 46).
Consistent with this idea are data implicating centrosome dysfunction
in CIN and aneuploidy in colon carcinoma cell lines (47).
Our work has important implications for prostate cancer progression,
Fig. 8. Centrosome-based model for prostate cancer progression. Diagram of normal
(above) and neoplastic prostate glands (below) showing the most salient cytoarchitectural
features of tumors with increasing Gleason grade. In our model, centrosomes (p) become
increasingly abnormal and misallocated during tumor progression, concurrent with ab-
normalities in nuclei and nucleoli (filled dot), cellular and glandular disorganization, and
chromosome instability. Filled arrows, currently favored evolutionary pathways; seg-
mented arrows, possible alternative pathways. Neither pathway has been convincingly
demonstrated for prostate carcinoma. Gleason grade I and prostatic intraepithelial neo-
plasm lesions are not represented.
Fig. 7. Permanent prostate tumor cell lines expressing pericentrin have
tumor-like features. A, Western blot after immunoprecipitation of HA-peri-
centrin from cell lysates. Centrosome defects were detected and quantified as
described in Fig. 6B. In situ hybridization with centromere probes to chro-
mosome 8 to evaluate chromosome instability (C and D) or with propidium
iodide to determine DNA content by flow cytometry (E and F) is shown. Y
axis, propidium iodide fluorescence. Changes in cellular architecture are
observed in HA-pericentrin cells (H) compared with controls (G, note larger
cells with larger nuclei). HA-pericentrin-expressing cells exhibit enhanced
growth in agarose (J) compared with controls (I), as shown by a significant
increase in colony size (K, Peri1) but not number (L, Peri1).
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prognosis, and treatment. Our observations suggest that progressive dys-
function of centrosomes occurs in prostate carcinoma, and that this can
have far-reaching effects on cell morphology and genetic composition.
Elucidating the mechanism(s) that leads to centrosome dysfunction in
prostate carcinoma and the fundamental differences between centrosomes
of low- and high-grade tumors could lead to the development of markers
for tumor virulence. Such markers could play a critical role in identifying
the subset of patients destined to develop aggressive, lethal prostate
carcinoma. For example, elevated levels of centrosome proteins could
provide a potential marker for early prostate lesions. If released into the
circulation like prostate-specific antigen, these proteins could provide a
noninvasive method to detect early lesions that lead to aggressive disease.
Centrosome abnormalities also constitute an attractive, novel therapeutic
target because they are tumor specific. It may be possible to develop
chemical inhibitors against molecular components of centrosomes, such
as pericentrin, that could correct or reverse centrosome defects, genetic
instability, and tumor progression.
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